Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
CPT: Pharmacometrics & Systems Pharmacology
|
April 25, 2022
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
Rob C Van Wijk, Ulrika S H Simonsson
British Journal of Clinical Pharmacology
|
May 6, 2015
Integration of PKPD relationships into benefit-risk analysis
Francesco Bellanti, Rob C van Wijk, Meindert Danhof, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 12, 2023
Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA)
Rob C van Wijk, Marjorie Z Imperial, Radojka M Savic, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
November 7, 2017
Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat
Yin Cheong Wong, Trayana Ilkova, Rob C van Wijk, et al.
Vaccines
|
March 28, 2024
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic
Laurynas Mockeliunas, Rob C van Wijk, Caryn M Upton, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 4, 2023
Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modeling
Rob C van Wijk, Laurynas Mockeliunas, Caryn M Upton, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 12, 2023
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
Alan Faraj, Rob C van Wijk, Linda Neuman, et al.
Scientific Reports
|
September 28, 2023
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
Rob C van Wijk, Laurynas Mockeliunas, Gerben van den Hoogen, et al.
Science Translational Medicine
|
February 5, 2025
Selection and prioritization of candidate combination regimens for the treatment of tuberculosis
Natasha Strydom, Rob C van Wijk, Qianwen Wang, et al.
Frontiers in Pharmacology
|
May 1, 2023
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
Laurynas Mockeliunas, Alan Faraj, Rob C van Wijk, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
CPT: Pharmacometrics & Systems Pharmacology
|
April 25, 2022
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
Rob C Van Wijk, Ulrika S H Simonsson
British Journal of Clinical Pharmacology
|
May 6, 2015
Integration of PKPD relationships into benefit-risk analysis
Francesco Bellanti, Rob C van Wijk, Meindert Danhof, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 12, 2023
Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA)
Rob C van Wijk, Marjorie Z Imperial, Radojka M Savic, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
November 7, 2017
Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat
Yin Cheong Wong, Trayana Ilkova, Rob C van Wijk, et al.
Vaccines
|
March 28, 2024
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic
Laurynas Mockeliunas, Rob C van Wijk, Caryn M Upton, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 4, 2023
Seasonal influence on respiratory tract infection severity including COVID-19 quantified through Markov Chain modeling
Rob C van Wijk, Laurynas Mockeliunas, Caryn M Upton, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 12, 2023
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
Alan Faraj, Rob C van Wijk, Linda Neuman, et al.
Scientific Reports
|
September 28, 2023
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
Rob C van Wijk, Laurynas Mockeliunas, Gerben van den Hoogen, et al.
Science Translational Medicine
|
February 5, 2025
Selection and prioritization of candidate combination regimens for the treatment of tuberculosis
Natasha Strydom, Rob C van Wijk, Qianwen Wang, et al.
Frontiers in Pharmacology
|
May 1, 2023
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
Laurynas Mockeliunas, Alan Faraj, Rob C van Wijk, et al.
Page
of 3